122 related articles for article (PubMed ID: 32194045)
1. Structural analysis of a natural apolipoprotein A-I variant (L60R) associated with amyloidosis.
Gaddi GM; Gisonno RA; Rosú SA; Curto LM; Prieto ED; Schinella GR; Finarelli GS; Cortez MF; Bauzá L; Elías EE; Ramella NA; Tricerri MA
Arch Biochem Biophys; 2020 May; 685():108347. PubMed ID: 32194045
[TBL] [Abstract][Full Text] [Related]
2. Amyloidogenic propensity of a natural variant of human apolipoprotein A-I: stability and interaction with ligands.
Rosú SA; Rimoldi OJ; Prieto ED; Curto LM; Delfino JM; Ramella NA; Tricerri MA
PLoS One; 2015; 10(5):e0124946. PubMed ID: 25950566
[TBL] [Abstract][Full Text] [Related]
3. Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity.
Ramella NA; Schinella GR; Ferreira ST; Prieto ED; Vela ME; Ríos JL; Tricerri MA; Rimoldi OJ
PLoS One; 2012; 7(8):e43755. PubMed ID: 22952757
[TBL] [Abstract][Full Text] [Related]
4. Molecular Insights into Human Hereditary Apolipoprotein A-I Amyloidosis Caused by the Glu34Lys Mutation.
Morgado I; Panahi A; Burwash AG; Das M; Straub JE; Gursky O
Biochemistry; 2018 Oct; 57(39):5738-5747. PubMed ID: 30184436
[TBL] [Abstract][Full Text] [Related]
5. Structural Stability and Local Dynamics in Disease-Causing Mutants of Human Apolipoprotein A-I: What Makes the Protein Amyloidogenic?
Das M; Wilson CJ; Mei X; Wales TE; Engen JR; Gursky O
J Mol Biol; 2016 Jan; 428(2 Pt B):449-62. PubMed ID: 26562506
[TBL] [Abstract][Full Text] [Related]
6. Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I.
Raimondi S; Guglielmi F; Giorgetti S; Di Gaetano S; Arciello A; Monti DM; Relini A; Nichino D; Doglia SM; Natalello A; Pucci P; Mangione P; Obici L; Merlini G; Stoppini M; Robustelli P; Tartaglia GG; Vendruscolo M; Dobson CM; Piccoli R; Bellotti V
J Mol Biol; 2011 Apr; 407(3):465-76. PubMed ID: 21296086
[TBL] [Abstract][Full Text] [Related]
7. Fibrillar conformation of an apolipoprotein A-I variant involved in amyloidosis and atherosclerosis.
Gisonno RA; Prieto ED; Gorgojo JP; Curto LM; Rodriguez ME; Rosú SA; Gaddi GM; Finarelli GS; Cortez MF; Schinella GR; Tricerri MA; Ramella NA
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129515. PubMed ID: 31904503
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
9. Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing - a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis.
Das M; Mei X; Jayaraman S; Atkinson D; Gursky O
FEBS J; 2014 Jun; 281(11):2525-42. PubMed ID: 24702826
[TBL] [Abstract][Full Text] [Related]
10. Effect of single point mutations in a form of systemic amyloidosis.
Bhavaraju M; Hansmann UH
Protein Sci; 2015 Sep; 24(9):1451-62. PubMed ID: 26105812
[TBL] [Abstract][Full Text] [Related]
11. Protein conformational perturbations in hereditary amyloidosis: Differential impact of single point mutations in ApoAI amyloidogenic variants.
Del Giudice R; Arciello A; Itri F; Merlino A; Monti M; Buonanno M; Penco A; Canetti D; Petruk G; Monti SM; Relini A; Pucci P; Piccoli R; Monti DM
Biochim Biophys Acta; 2016 Feb; 1860(2):434-44. PubMed ID: 26515634
[TBL] [Abstract][Full Text] [Related]
12. Understanding the role of apolipoproteinA-I in atherosclerosis. Post-translational modifications synergize dysfunction?
Ludovico ID; Gisonno RA; Gonzalez MC; Garda HA; Ramella NA; Tricerri MA
Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129732. PubMed ID: 32946930
[TBL] [Abstract][Full Text] [Related]
13. Learning from Synthetic Models of Extracellular Matrix; Differential Binding of Wild Type and Amyloidogenic Human Apolipoprotein A-I to Hydrogels Formed from Molecules Having Charges Similar to Those Found in Natural GAGs.
Rosú SA; Toledo L; Urbano BF; Sanchez SA; Calabrese GC; Tricerri MA
Protein J; 2017 Aug; 36(4):374-383. PubMed ID: 28634774
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein A-I: the dual face of a protein.
Arciello A; Piccoli R; Monti DM
FEBS Lett; 2016 Dec; 590(23):4171-4179. PubMed ID: 27790714
[TBL] [Abstract][Full Text] [Related]
15. Data regarding the sensibility to proteolysis of a natural apolipoprotein A-I mutant.
Gaddi GM; Gisonno RA; Rosú SA; Cortez MF; Finarelli GS; Ramella NA; Tricerri MA
Data Brief; 2020 Aug; 31():105960. PubMed ID: 32676531
[TBL] [Abstract][Full Text] [Related]
16. Structural and Functional Analysis of the ApolipoproteinA-I A164S Variant.
Dalla-Riva J; Lagerstedt JO; Petrlova J
PLoS One; 2015; 10(11):e0143915. PubMed ID: 26605794
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants in ApoA-I amyloidogenic variants explain improved cholesterol metabolism despite low HDL levels.
Del Giudice R; Domingo-Espín J; Iacobucci I; Nilsson O; Monti M; Monti DM; Lagerstedt JO
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3038-3048. PubMed ID: 28887204
[TBL] [Abstract][Full Text] [Related]
18. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines.
Sipe JD; Benson MD; Buxbaum JN; Ikeda SI; Merlini G; Saraiva MJ; Westermark P
Amyloid; 2016 Dec; 23(4):209-213. PubMed ID: 27884064
[TBL] [Abstract][Full Text] [Related]
19. Heparin promotes fibril formation by the N-terminal fragment of amyloidogenic apolipoprotein A-I.
Mikawa S; Mizuguchi C; Nishitsuji K; Baba T; Shigenaga A; Shimanouchi T; Sakashita N; Otaka A; Akaji K; Saito H
FEBS Lett; 2016 Oct; 590(20):3492-3500. PubMed ID: 27654470
[TBL] [Abstract][Full Text] [Related]
20. Mutation mapping of apolipoprotein A-I structure assisted with the putative cholesterol recognition regions.
Dergunov AD
Biochim Biophys Acta; 2013 Oct; 1834(10):2030-5. PubMed ID: 23806608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
